{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:59Z","timestamp":1793924579756,"version":"4.8.0"},"reference-count":193,"publisher":"Bentham Science Publishers Ltd.","issue":"36","funder":[{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2018R01015"],"award-info":[{"award-number":["2018R01015"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177105"],"award-info":[{"award-number":["22177105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LY19B020008"],"award-info":[{"award-number":["LY19B020008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New-shoot Talents Program of Zhejiang Province","award":["2022R403B082"],"award-info":[{"award-number":["2022R403B082"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Many drugs have adverse absorption, distribution, metabolism, and excretory\n(ADME) properties that prevent their widespread use or limit their use in some indications.\nIn addition to preparation techniques and prodrug strategies, deuterium modification\nis a viable method for improving ADME properties. Deuterated drugs have attracted\nincreasing attention from the pharmaceutical industry in recent years. To date, two deuterated\ndrugs have been approved by the FDA. In 2017, austedo was approved by the FDA\nas a new drug for Huntington's disease in the United States, the first deuterium drug to be\nmarketed worldwide. Recently (June 9, 2021), donafinil has been listed in China; this result\nhas caused major pharmaceutical companies and the pharmaceutical industry to pay\nattention to deuterium technology again. In addition, BMS-986165, RT001, ALK-001,\nHC-1119, AVP-786 and other drugs are in phase III clinical studies, and some solid deuterium\ncompounds have entered phase I and II clinical trials. The deuterium strategy has\nbeen widely used in pharmaceutical research and has become a hot spot in pharmaceutical\nresearch in recent years. In this paper, the research and development of deuterated\ndrugs are reviewed, and the influence of deuterium modification on drugs, the advantages\nof deuterium strategies and the synthesis strategies of deuterated drugs are mainly\nintroduced. Hoping to provide references for clinical application, the discovery of new\ndeuterium chemical entities and research and development of new deuterated drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867330666221122123201","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T23:33:51Z","timestamp":1669160031000},"page":"4096-4129","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Application and Synthesis Methods of Deuterated Drugs"],"prefix":"10.2174","volume":"30","author":[{"given":"Xiao-Liang","family":"Xu","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P.R. China"},{"name":"Institute of Drug Development &amp; Chemical Biology, Zhejiang University of Technology, Hangzhou\n310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P.R. China"},{"name":"Institute of Drug Development &amp; Chemical Biology, Zhejiang University of Technology, Hangzhou\n310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P.R. China"},{"name":"Institute of Drug Development &amp; Chemical Biology, Zhejiang University of Technology, Hangzhou\n310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1039\/c0an00956c","volume":"136","author":"Bergner G.","year":"2011","unstructured":"Bergner G.; Albert C.R.; Schiller M.; Bringmann G.; Schirmeister T.; Dietzek B.; Niebling S.; Schl\u00fccker S.; Popp J.; Quantitative detection of C-deuterated drugs by CARS microscopy and Raman microspectroscopy. Analyst (Lond) 2011,136(18),3686-3693","journal-title":"Analyst (Lond)"},{"key":"ref=2","first-page":"339","volume":"242","author":"Liu J.F.","year":"2011","unstructured":"Liu J.F.; Uttamsingh V.; Nguyen S.; Gallegos R.; Bridson G.W.; Morgan A.J.; Masse C.E.; Tung R.; Harbeson S.; Deuterium in drugs for cardiovascular disease: Design and synthesis of deuterated cilostazol and ranolazine analogs with enhanced metabolic stability. Am Chem Soc 2011,242,339","journal-title":"Am Chem Soc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"Timmins G.S.","year":"2014","unstructured":"Timmins G.S.; Deuterated drugs: Where are we now? Expert Opin Ther Pat 2014,24(10),1067-1075","journal-title":"Expert Opin Ther Pat"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"02793695-20150821-55","DOI":"10.3928\/02793695-20150821-55","volume":"53","author":"Howland R.H.","year":"2015","unstructured":"Howland R.H.; Deuterated drugs. J Psychosoc Nurs Ment Health Serv 2015,53(9),02793695-20150821-55","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"ref=5","first-page":"748","volume":"109","author":"Radl S.","year":"2015","unstructured":"Radl S.; Deuterated compounds as potential drugs. Chem Listy 2015,109(10),748-754","journal-title":"Chem Listy"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd.2016.63","volume":"15","author":"Mullard A.","year":"2016","unstructured":"Mullard A.; Deuterated drugs draw heavier backing. Nat Rev Drug Discov 2016,15(4),219-221","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/13543776.2017.1378350","volume":"27","author":"Timmins G.S.","year":"2017","unstructured":"Timmins G.S.; Deuterated drugs; Updates and obviousness analysis. Expert Opin Ther Pat 2017,27(12),1353-1361","journal-title":"Expert Opin Ther Pat"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nbt0617-493","volume":"35","author":"Schmidt C.","year":"2017","unstructured":"Schmidt C.; First deuterated drug approved. Nat Biotechnol 2017,35(6),493-494","journal-title":"Nat Biotechnol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/jpet.117.241497","volume":"362","author":"Harbeson S.L.","year":"2017","unstructured":"Harbeson S.L.; Morgan A.J.; Liu J.F.; Aslanian A.M.; Nguyen S.; Bridson G.W.; Brummel C.L.; Wu L.; Tung R.D.; Pilja L.; Braman V.; Uttamsingh V.; Altering metabolic profiles of drugs by precision deuteration 2: Discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther 2017,362(2),359-367","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/13543776.2018.1502972","volume":"28","author":"Timmins G.S.","year":"2018","unstructured":"Timmins G.S.; Deuterated drugs; Updates and obviousness analysis. Expert Opin Ther Pat 2018,28(8),653-653","journal-title":"Expert Opin Ther Pat"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acs.biochem.7b00765","volume":"57","author":"DeWitt S.H.","year":"2018","unstructured":"DeWitt S.H.; Maryanoff B.E.; Deuterated drug molecules: Focus on FDA-Approved deutetrabenazine. Biochemistry 2018,57(5),472-473","journal-title":"Biochemistry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"107850","DOI":"10.1016\/j.drugalcdep.2020.107850","volume":"208","author":"Berquist M.D.","year":"2020","unstructured":"Berquist M.D.; Leth-Petersen S.; Kristensen J.L.; Fantegrossi W.E.; In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation. Drug Alcohol Depend 2020,208,107850","journal-title":"Drug Alcohol Depend"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.drudis.2020.03.014","volume":"25","author":"Demidov V.V.","year":"2020","unstructured":"Demidov V.V.; Site-specifically deuterated essential lipids as new drugs against neuronal, retinal and vascular degeneration. Drug Discov Today 2020,25(8),1469-1476","journal-title":"Drug Discov Today"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"113338","DOI":"10.1016\/j.jpba.2020.113338","volume":"187","author":"Samuels E.R.","year":"2020","unstructured":"Samuels E.R.; Wang T.; Quantitative H NMR analysis of a difficult drug substance and its exo-isomer as hydrochloride salts using alkaline deuterated methanol. J Pharm Biomed Anal 2020,187,113338","journal-title":"J Pharm Biomed Anal"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/jlcr.3880","volume":"63","author":"Makarova M.","year":"2020","unstructured":"Makarova M.; Barrientos R.C.; Torres O.B.; Matyas G.R.; Jacobson A.E.; Sulima A.; Rice K.C.; Synthesis of a deuterated 6-AmHap internal standard for the determination of hapten density in a heroin vaccine drug product. J Labelled Comp Radiopharm 2020,63(13),564-571","journal-title":"J Labelled Comp Radiopharm"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/0165-6147(84)90534-0","volume":"5","author":"Foster A.B.","year":"1984","unstructured":"Foster A.B.; Deuterium isotope effects in studies of drug metabolism. Trends Pharmacol Sci 1984,5,524-527","journal-title":"Trends Pharmacol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1002\/anie.201610837","volume":"56","author":"Cooper G.J.T.","year":"2017","unstructured":"Cooper G.J.T.; Surman A.J.; McIver J.; Col\u00f3n-Santos S.M.; Gromski P.S.; Buchwald S.; Su\u00e1rez Marina I.; Cronin L.; Miller-Urey spark-discharge experiments in the deuterium world. Angew Chem Int Ed 2017,56(28),8079-8082","journal-title":"Angew Chem Int Ed"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1021\/jm1013693","volume":"54","author":"Meanwell N.A.","year":"2011","unstructured":"Meanwell N.A.; Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011,54(8),2529-2591","journal-title":"J Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/cs9740300513","volume":"3","author":"Bell R.P.","year":"1974","unstructured":"Bell R.P.; Liversidge Lecture. Recent advances in the study of kinetic hydrogen isotope effects. Chem Soc Rev 1974,3(4),513-544","journal-title":"Chem Soc Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/0006-291X(89)92511-4","volume":"160","author":"Ling K.H.J.","year":"1989","unstructured":"Ling K.H.J.; Hanzlik R.P.; Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis. Biochem Biophys Res Commun 1989,160(2),844-849","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.134.3485.1078","volume":"134","author":"Elison C.","year":"1961","unstructured":"Elison C.; Rapoport H.; Laursen R.; Elliott H.W.; Effect of deuteration of N-CH group on potency and enzymatic N-demethylation of morphine. Science 1961,134(3485),1078-1079","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1021\/cr60211a004","volume":"61","author":"Westheimer F.H.","year":"1961","unstructured":"Westheimer F.H.; The magnitude of the primary kinetic isotope effect for compounds of hydrogen and deuterium. Chem Rev 1961,61(3),265-273","journal-title":"Chem Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1055\/s-0031-1296622","volume":"57","author":"Schneider F.","year":"2011","unstructured":"Schneider F.; Mattern-Dogru E.; Hillgenberg M.; Alken R.G.; Changed phosphodiesterase selectivity and enhanced in vitro efficacy by selective deuteration of sildenafil. Arzneimittelforschung 2011,57(6),293-298","journal-title":"Arzneimittelforschung"},{"key":"ref=24","first-page":"716","volume":"214","author":"Sipes I.G.","year":"1980","unstructured":"Sipes I.G.; Gandolfi A.J.; Pohl L.R.; Krishna G.; Brown B.R.; Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther 1980,214(3),716-720","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=25","first-page":"668","volume":"14","author":"Darland G.K.","year":"1986","unstructured":"Darland G.K.; Hajdu R.; Kropp H.; Kahan F.M.; Walker R.W.; Vandenheuvel W.J.; Oxidative and defluorinative metabolism of fludalanine, 2-2H-3-fluoro-D-alanine. Drug Metab Dispos 1986,14(6),668-673","journal-title":"Drug Metab Dispos"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpba.2016.04.033","volume":"130","author":"Higashi T.","year":"2016","unstructured":"Higashi T.; Ogawa S.; Isotope-coded ESI-enhancing derivatization reagents for differential analysis, quantification and profiling of metabolites in biological samples by LC\/MS: A review. J Pharm Biomed Anal 2016,130,181-193","journal-title":"J Pharm Biomed Anal"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1358\/dnp.2010.23.6.1426638","volume":"23","author":"Shao L.","year":"2010","unstructured":"Shao L.; Hewitt M.C.; The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 2010,23(6),398-404","journal-title":"Drug News Perspect"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1139\/cjr35-005","volume":"12","author":"Cleave A.B.V.","year":"1935","unstructured":"Cleave A.B.V.; Maass O.; The molecular diameter of deuterium as determined by viscosity measurements. Can J Res 1935,12(1),57-62","journal-title":"Can J Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1063\/1.1703223","volume":"42","author":"Bartell L.S.","year":"1965","unstructured":"Bartell L.S.; Roth E.A.; Hollowell C.D.; Kuchitsu K.; Young J.E.; Electron-diffraction study of the structures of CH and CD. J Chem Phys 1965,42(8),2683-2686","journal-title":"J Chem Phys"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1063\/1.1669897","volume":"49","author":"Kuchitsu K.","year":"1968","unstructured":"Kuchitsu K.; Comparison of molecular structures determined by electron diffraction and spectroscopy. Ethane and diborane. J Chem Phys 1968,49(10),4456-4462","journal-title":"J Chem Phys"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrd.2017.89","volume":"16","author":"Mullard A.","year":"2017","unstructured":"Mullard A.; FDA approves first deuterated drug. Nat Rev Drug Discov 2017,16(5),305-305","journal-title":"Nat Rev Drug Discov"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"14985","DOI":"10.1021\/acs.analchem.1c02283","volume":"93","author":"Miyagi M.","year":"2021","unstructured":"Miyagi M.; Tanaka K.; Watanabe S.; Kondo J.; Kishimoto T.; Identifying protein\u2013drug interactions in cell lysates using histidine hydrogen deuterium exchange. Anal Chem 2021,93(45),14985-14995","journal-title":"Anal Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/bies.20681","volume":"29","author":"Shchepinov M.S.","year":"2007","unstructured":"Shchepinov M.S.; Do \u201cheavy\u201d eaters live longer? BioEssays 2007,29(12),1247-1256","journal-title":"BioEssays"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/rej.2006.0506","volume":"10","author":"Shchepinov M.S.","year":"2007","unstructured":"Shchepinov M.S.; Reactive oxygen species, isotope effect, essential nutrients, and enhanced longevity. Rejuvenat Res 2007,10(1),47-60","journal-title":"Rejuvenat Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/936486","volume":"2012","author":"Alfadda A.A.","year":"2012","unstructured":"Alfadda A.A.; Sallam R.M.; Reactive oxygen species in health and disease. J Biomed Biotechnol 2012,2012(6),1-14","journal-title":"J Biomed Biotechnol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"w13659","DOI":"10.4414\/smw.2012.13659","volume":"142","author":"Brieger K.","year":"2012","unstructured":"Brieger K.; Schiavone S.; Miller J.; Krause K.H.; Reactive oxygen species: From health to disease. Swiss Med Wkly 2012,142,w13659","journal-title":"Swiss Med Wkly"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.freeradbiomed.2012.09.027","volume":"62","author":"Sultana R.","year":"2013","unstructured":"Sultana R.; Perluigi M.; Butterfield D.A.; Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med 2013,62,157-169","journal-title":"Free Radic Biol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3164\/jcbn.14-10","volume":"54","author":"Shichiri M.","year":"2014","unstructured":"Shichiri M.; The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr 2014,54(3),151-160","journal-title":"J Clin Biochem Nutr"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/brain\/aww174","volume":"139","author":"Farrar M.A.","year":"2016","unstructured":"Farrar M.A.; Teoh H.L.; Brammah S.; Roscioli T.; Cardamone M.; Glial mitochondropathy in infantile neuroaxonal dystrophy: Pathophysiological and therapeutic implications. Brain 2016,139(12),e67","journal-title":"Brain"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00000542-197908000-00003","volume":"51","author":"McCarty L.P.","year":"1979","unstructured":"McCarty L.P.; Malek R.S.; Larsen E.R.; The effects of deuteration on the metabolism of halogenated anesthetics in the rat. Anesthesiology 1979,51(2),106-110","journal-title":"Anesthesiology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.xphs.2021.03.006","volume":"110","author":"Cho E.","year":"2021","unstructured":"Cho E.; Mayhugh B.M.; Srinivasan J.M.; Sacha G.A.; Nail S.L.; Topp E.M.; Stability of antibody drug conjugate formulations evaluated using solid-state hydrogen-deuterium exchange mass spectrometry. J Pharm Sci 2021,110(6),2379-2385","journal-title":"J Pharm Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1021\/jm901023f","volume":"52","author":"Maltais F.","year":"2009","unstructured":"Maltais F.; Jung Y.C.; Chen M.; Tanoury J.; Perni R.B.; Mani N.; Laitinen L.; Huang H.; Liao S.; Gao H.; Tsao H.; Block E.; Ma C.; Shawgo R.S.; Town C.; Brummel C.L.; Howe D.; Pazhanisamy S.; Raybuck S.; Namchuk M.; Bennani Y.L.; In vitro and in vivo isotope effects with hepatitis C protease inhibitors: Enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem 2009,52(24),7993-8001","journal-title":"J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/cpdd.1040","volume":"11","author":"Chen M.C.","year":"2022","unstructured":"Chen M.C.; Korth C.C.; Harnett M.D.; Elenko E.; Lickliter J.D.; A randomized phase 1 evaluation of deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases. Clin Pharmacol Drug Dev 2022,11(2),220-234","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-0031-1296724","volume":"56","author":"Schneider F.","year":"2011","unstructured":"Schneider F.; Hillgenberg M.; Koytchev R.; Alken R.G.; Enhanced plasma concentration by selective deuteration of rofecoxib in rats. Arzneimittelforschung 2011,56(4),295-300","journal-title":"Arzneimittelforschung"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/jm1010995","volume":"54","author":"Kerekes A.D.","year":"2011","unstructured":"Kerekes A.D.; Esposite S.J.; Doll R.J.; Tagat J.R.; Yu T.; Xiao Y.; Zhang Y.; Prelusky D.B.; Tevar S.; Gray K.; Terracina G.A.; Lee S.; Jones J.; Liu M.; Basso A.D.; Smith E.B.; Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: Fluorine and deuterium incorporation improve oral absorption and exposure. J Med Chem 2011,54(1),201-210","journal-title":"J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/jm401780b","volume":"57","author":"Xu G.","year":"2014","unstructured":"Xu G.; Lv B.; Roberge J.Y.; Xu B.; Du J.; Dong J.; Chen Y.; Peng K.; Zhang L.; Tang X.; Feng Y.; Xu M.; Fu W.; Zhang W.; Zhu L.; Deng Z.; Sheng Z.; Welihinda A.; Sun X.; Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes. J Med Chem 2014,57(4),1236-1251","journal-title":"J Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.133.3446.102","volume":"133","author":"Belleau B.","year":"1961","unstructured":"Belleau B.; Burba J.; Pindell M.; Reiffenstein J.; Effect of deuterium substitution in sympathumimetic amines on adrenergic responses. Science 1961,133(3446),102-104","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.4155\/fmc-2019-0183","volume":"11","author":"Cargnin S.","year":"2019","unstructured":"Cargnin S.; Serafini M.; Pirali T.; A primer of deuterium in drug design. Future Med Chem 2019,11(16),2039-2042","journal-title":"Future Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/B978-0-12-386009-5.00003-5","volume":"46","author":"Harbeson S.L.","year":"2011","unstructured":"Harbeson S.L.; Tung R.D.; Deuterium in drug discovery and development. Annu Rep Med Chem 2011,46,403-417","journal-title":"Annu Rep Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","volume":"62","author":"Pirali T.","year":"2019","unstructured":"Pirali T.; Serafini M.; Cargnin S.; Genazzani A.A.; Applications of deuterium in medicinal chemistry. J Med Chem 2019,62(11),5276-5297","journal-title":"J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"14570","DOI":"10.1021\/jacs.9b08662","volume":"141","author":"Chang Y.","year":"2019","unstructured":"Chang Y.; Yesilcimen A.; Cao M.; Zhang Y.; Zhang B.; Chan J.Z.; Wasa M.; Catalytic deuterium incorporation within metabolically stable \u03b2-Amino C\u2013H bonds of drug molecules. J Am Chem Soc 2019,141(37),14570-14575","journal-title":"J Am Chem Soc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.disamonth.2004.10.001","volume":"50","author":"Ahn J.","year":"2004","unstructured":"Ahn J.; Flamm S.L.; Hepatocellular carcinoma. Dis Mon 2004,50(10),556-573","journal-title":"Dis Mon"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.33545","volume":"149","author":"Morisue R.","year":"2021","unstructured":"Morisue R.; Kojima M.; Suzuki T.; Nakatsura T.; Ojima H.; Watanabe R.; Sugimoto M.; Kobayashi S.; Takahashi S.; Konishi M.; Ishii G.; Gotohda N.; Fujiwara T.; Ochiai A.; Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. Int J Cancer 2021,149(3),546-560","journal-title":"Int J Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/cancers13040783","volume":"13","author":"Iscan E.","year":"2021","unstructured":"Iscan E.; Ekin U.; Yildiz G.; Oz O.; Keles U.; Suner A.; Cakan-Akdogan G.; Ozhan G.; Nekulova M.; Vojtesek B.; Uzuner H.; Karak\u00fclah G.; Alotaibi H.; Ozturk M.; TAp73\u03b2 can promote hepatocellular carcinoma dedifferentiation. Cancers 2021,13(4),783","journal-title":"Cancers"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e13030","DOI":"10.1111\/ijcp.13030","volume":"71","author":"Citrome L.","year":"2017","unstructured":"Citrome L.; Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2017,71(11),e13030","journal-title":"Int J Clin Pract"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.0970","volume":"316","author":"Frank S.","year":"2016","unstructured":"Frank S.; Testa C.M.; Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. JAMA 2016,316(1),40-50","journal-title":"JAMA"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"Frank S.","year":"2017","unstructured":"Frank S.; Stamler D.; Kayson E.; Claassen D.O.; Colcher A.; Davis C.; Duker A.; Eberly S.; Elmer L.; Furr-Stimming E.; Gudesblatt M.; Hunter C.; Jankovic J.; Kostyk S.K.; Kumar R.; Loy C.; Mallonee W.; Oakes D.; Scott B.L.; Sung V.; Goldstein J.; Vaughan C.; Testa C.M.; Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol 2017,74(8),977-982","journal-title":"JAMA Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"Jankovic J.","year":"2016","unstructured":"Jankovic J.; Jimenez-Shahed J.; Budman C.; Coffey B.; Murphy T.; Shprecher D.; Stamler D.; A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov 2016,6(0),422","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1080\/14656566.2019.1674281","volume":"20","author":"Daniel O.C.","year":"2019","unstructured":"Daniel O.C.; Michael P.; Benjamin C.; Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington\u2019s disease: A review of clinical trial data. Expert opin pharmaco 2019,20(18),2209-2221","journal-title":"Expert opin pharmaco"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2045125319847882","DOI":"10.1177\/2045125319847882","volume":"9","author":"Patel R.S.","year":"2019","unstructured":"Patel R.S.; Mansuri Z.; Motiwala F.; Saeed H.; Jannareddy N.; Patel H.; Zafar M.K.; A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol 2019,9,2045125319847882","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/DDDT.S138828","volume":"12","author":"Dean M.","year":"2018","unstructured":"Dean M.; Sung V.; Review of deutetrabenazine: A novel treatment for chorea associated with Huntington\u2019s disease. Drug Des Devel Ther 2018,12,313-319","journal-title":"Drug Des Devel Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cpdd.882","volume":"10","author":"Schneider F.","year":"2021","unstructured":"Schneider F.; Stamler D.; Bradbury M.; Loupe P.S.; Hellriegel E.; Cox D.S.; Savola J.M.; Gordon M.F.; Rabinovich-Guilatt L.; Pharmacokinetics of deutetrabenazine and tetrabenazine: Dose proportionality and food effect. Clin Pharmacol Drug Dev 2021,10(6),647-659","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14737175.2021.1848548","volume":"21","author":"Dorfman B.J.","year":"2021","unstructured":"Dorfman B.J.; Jimenez-Shahed J.; Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert Rev Neurother 2021,21(1),9-20","journal-title":"Expert Rev Neurother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","volume":"14","author":"Ferguson M.W.","year":"2022","unstructured":"Ferguson M.W.; Kennedy C.J.; Palpagama T.H.; Waldvogel H.J.; Faull R.L.M.; Kwakowsky A.; Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis 2022,14,11795735221092517","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","volume":"18","author":"Bashir H.","year":"2018","unstructured":"Bashir H.; Jankovic J.; Deutetrabenazine for the treatment of Huntington\u2019s chorea. Expert Rev Neurother 2018,18(8),625-631","journal-title":"Expert Rev Neurother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"Jankovic J.","year":"2016","unstructured":"Jankovic J.; Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016,17(18),2461-2470","journal-title":"Expert Opin Pharmacother"},{"key":"ref=67","year":"2017","unstructured":"Pharmaceuticals USA Inc. AUSTEDO (deutetrabenazine): US prescribing information. FDAAvailable from:  [Accessed on 14 May 2018].2017"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1358\/dot.2017.53.2.2589164","volume":"53","author":"Paton D.M.","year":"2017","unstructured":"Paton D.M.; Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington\u2019s disease, tardive dyskinesia and Tourette syndrome. Drugs Today (Barc) 2017,53(2),89-102","journal-title":"Drugs Today (Barc)"},{"key":"ref=69","author":"Reddy P.","unstructured":"Reddy P.; Procress for preparetion of ((3R.llbR)-1,3,4,6,7,11b-hexahydro-9,10- di(methoxy-d3)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one. WO  Patent 2,019,207,517 Al, October 31, 2019"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acs.oprd.8b00011","volume":"22","author":"Ray P.C.","year":"2018","unstructured":"Ray P.C.; Pawar Y.D.; Singare D.T.; Deshpande T.N.; Singh G.P.; Novel process for preparation of tetrabenazine and deutetrabenazine. Org Process Res Dev 2018,22(4),520-526","journal-title":"Org Process Res Dev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"Siegel R.L.","year":"2016","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2016. CA Cancer J Clin 2016,66(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"Chen W.","year":"2016","unstructured":"Chen W.; Zheng R.; Baade P.D.; Zhang S.; Zeng H.; Bray F.; Jemal A.; Yu X.Q.; He J.; Cancer statistics in China, 2015. CA Cancer J Clin 2016,66(2),115-132","journal-title":"CA Cancer J Clin"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"Llovet J.M.","year":"2008","unstructured":"Llovet J.M.; Ricci S.; Mazzaferro V.; Hilgard P.; Gane E.; Blanc J.F.; de Oliveira A.C.; Santoro A.; Raoul J.L.; Forner A.; Schwartz M.; Porta C.; Zeuzem S.; Bolondi L.; Greten T.F.; Galle P.R.; Seitz J.F.; Borbath I.; H\u00e4ussinger D.; Giannaris T.; Shan M.; Moscovici M.; Voliotis D.; Bruix J.; Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008,359(4),378-390","journal-title":"N Engl J Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"Escudier B.","year":"2007","unstructured":"Escudier B.; Eisen T.; Stadler W.M.; Szczylik C.; Oudard S.; Siebels M.; Negrier S.; Chevreau C.; Solska E.; Desai A.A.; Rolland F.; Demkow T.; Hutson T.E.; Gore M.; Freeman S.; Schwartz B.; Shan M.; Simantov R.; Bukowski R.M.; Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 2007,356(2),125-134","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1691\/ph.2019.9626","volume":"74","author":"Liu J.","year":"2019","unstructured":"Liu J.; Li X.; Zhang H.; Chen G.; Chen H.; Hu Y.; Niu J.; Ding Y.; Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. Pharmazie 2019,74(11),688-693","journal-title":"Pharmazie"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"Llovet J.","year":"2003","unstructured":"Llovet J.; Bruix J.; Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003,37(2),429-442","journal-title":"Hepatology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1021\/jm4007998","volume":"57","author":"Gant T.G.","year":"2014","unstructured":"Gant T.G.; Using deuterium in drug discovery: Leaving the label in the drug. J Med Chem 2014,57(9),3595-3611","journal-title":"J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nm0613-656","volume":"19","author":"Katsnelson A.","year":"2013","unstructured":"Katsnelson A.; Heavy drugs draw heavy interest from pharma backers. Nat Med 2013,19(6),656-656","journal-title":"Nat Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-020-04031-1","volume":"85","author":"Li X.","year":"2020","unstructured":"Li X.; Qiu M.; Wang S.; Zhu H.; Feng B.; Zheng L.; A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol 2020,85(3),593-604","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1089\/thy.2020.0235","volume":"31","author":"Lin Y.S.","year":"2021","unstructured":"Lin Y.S.; Yang H.; Ding Y.; Cheng Y.Z.; Shi F.; Tan J.; Deng Z.Y.; Chen Z.D.; Wang R.F.; Ji Q.H.; Huang R.; Li L.F.; Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II Trial. Thyroid 2021,31(4),607-615","journal-title":"Thyroid"},{"key":"ref=81","unstructured":"PubChem. National Center for Biotechnology Information. PubChem Compound Summary for CID 25191001, Donafenib Available from:  [Accessed on: January 25, 2021]."},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e26373","DOI":"10.1097\/MD.0000000000026373","volume":"100","author":"Li Q.","year":"2021","unstructured":"Li Q.; Zhu H.; Donafenib treatment for hepatocellular carcinoma. Medicine (Baltimore) 2021,100(25),e26373","journal-title":"Medicine (Baltimore)"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2020.38.15_suppl.4506","volume":"38","author":"Bi F.","year":"2020","unstructured":"Bi F.; Qin S.; Gu S.; Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II\/III trial. J Clin Oncol 2020,38(15 Suppl.),4506-4506","journal-title":"J Clin Oncol"},{"key":"ref=84","author":"Feng W.D.","year":"2015","unstructured":"Feng W.D.; Gao X.Y.; Dai X.J.; Preparation method of fluoro-substituted deuterated diphenylurea. 2015"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"Wrobleski S.T.","year":"2019","unstructured":"Wrobleski S.T.; Moslin R.; Lin S.; Zhang Y.; Spergel S.; Kempson J.; Tokarski J.S.; Strnad J.; Zupa-Fernandez A.; Cheng L.; Shuster D.; Gillooly K.; Yang X.; Heimrich E.; McIntyre K.W.; Chaudhry C.; Khan J.; Ruzanov M.; Tredup J.; Mulligan D.; Xie D.; Sun H.; Huang C.; D\u2019Arienzo C.; Aranibar N.; Chiney M.; Chimalakonda A.; Pitts W.J.; Lombardo L.; Carter P.H.; Burke J.R.; Weinstein D.S.; Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165. J Med Chem 2019,62(20),8973-8995","journal-title":"J Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.1093\/ecco-jcc\/jjy222.473","volume":"13","author":"Chimalakonda A.","year":"2019","unstructured":"Chimalakonda A.; Jones J.; Dockens R.; Throup J.; Banerjee S.; Girgis I.; P349 Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects. J Crohn\u2019s Colitis 2019,13(Suppl. 1),S277-S278","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1316.1","DOI":"10.1136\/annrheumdis-2020-eular.4598","volume":"79","author":"Chimalakonda A.","year":"2020","unstructured":"Chimalakonda A.; Burke J.; Cheng L.; Strnad J.; Catlett I.; Patel A.; Shen J.; Girgis I.; Banerjee S.; Throup J.; Selective inhibiton of tyrosine kinase 2 with an oral agent, BMS-986165, compared with janus kinase inhibitors. Ann Rheum Dis 2020,79(Suppl. 1),1316.1-1316","journal-title":"Ann Rheum Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"AB12","DOI":"10.1016\/j.jaad.2019.06.083","volume":"81","author":"Krueger J.","year":"2019","unstructured":"Krueger J.; Hu S.; Banerjee S.; Gordon K.; Catlett I.; A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis. J Am Acad Dermatol 2019,81(4),AB12-AB12","journal-title":"J Am Acad Dermatol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.dmpk.2020.04.178","volume":"35","author":"Yao M.","year":"2020","unstructured":"Yao M.; Gu X.; Brailsford J.; Cortes J.C.; Iyer R.; Li W.; P177 - Comparative metabolism of [14C]-BMS-986165 in mice, rats, monkey, and humans. Drug Metab Pharmacokinet 2020,35(1),S77-S77","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"859.1","DOI":"10.1136\/annrheumdis-2017-eular.3809","volume":"76","author":"Catlett I.","year":"2017","unstructured":"Catlett I.; Aras U.; Liu Y.; Bei D.; Girgis I.; Murthy B.; Honczarenko M.; Rose S.; A first-in -human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Ann Rheum Dis 2017,76,859.1-859","journal-title":"Ann Rheum Dis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14728222.2014.892925","volume":"18","author":"Liang Y.","year":"2014","unstructured":"Liang Y.; Zhu Y.; Xia Y.; Peng H.; Yang X.K.; Liu Y.Y.; Xu W.D.; Pan H.F.; Ye D.Q.; Therapeutic potential of tyrosine kinase 2 in autoimmunity. Expert Opin Ther Targets 2014,18(5),571-580","journal-title":"Expert Opin Ther Targets"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1093\/ecco-jcc\/jjy222.762","volume":"13","author":"Chimalakonda A.","year":"2019","unstructured":"Chimalakonda A.; Jones J.; Dockens R.; Throup J.; Banerjee S.; Girgis I.; P638 BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects. J Crohn\u2019s Colitis 2019,13(Suppl. 1),S437-S438","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=93","author":"Gao P.","year":"2020","unstructured":"Gao P.; Zeng M.; Tan S.L.; Sun G.J.; Wang S.B.; Xiu W.H.; Bao R.D.; The utility model relates to a pyridazine derivative inhibitor, a preparation method and application thereof. 2020"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","volume":"256","author":"Pandolfo M.","year":"2009","unstructured":"Pandolfo M.; Friedreich ataxia: the clinical picture. J Neurol 2009,256(l 1),3-8","journal-title":"J Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","volume":"125","author":"Weidemann F.","year":"2012","unstructured":"Weidemann F.; Rummey C.; Bijnens B.; St\u00f6rk S.; Jasaityte R.; Dhooge J.; Baltabaeva A.; Sutherland G.; Schulz J.B.; Meier T.; The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 2012,125(13),1626-1634","journal-title":"Circulation"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"Patel M.","year":"2016","unstructured":"Patel M.; Isaacs C.J.; Seyer L.; Brigatti K.; Gelbard S.; Strawser C.; Foerster D.; Shinnick J.; Schadt K.; Yiu E.M.; Delatycki M.B.; Perlman S.; Wilmot G.R.; Zesiewicz T.; Mathews K.; Gomez C.M.; Yoon G.; Subramony S.H.; Brocht A.; Farmer J.; Lynch D.R.; Progression of Friedreich ataxia: Quantitative characterization over 5 years. Ann Clin Transl Neurol 2016,3(9),684-694","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.freeradbiomed.2012.06.004","volume":"53","author":"Hill S.","year":"2012","unstructured":"Hill S.; Lamberson C.R.; Xu L.; To R.; Tsui H.S.; Shmanai V.V.; Bekish A.V.; Awad A.M.; Marbois B.N.; Cantor C.R.; Porter N.A.; Clarke C.F.; Shchepinov M.S.; Small amounts of isotope-reinforced polyunsaturated fatty acids suppress lipid autoxidation. Free Radic Biol Med 2012,53(4),893-906","journal-title":"Free Radic Biol Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/21678421.2018.1549531","volume":"20","author":"Bedlack R.","year":"2019","unstructured":"Bedlack R.; ALSUntangled No. 47: RT001. Amyotroph Lateral Scler Frontotemporal Degener 2019,20(3-4),294-297","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mds.27353","volume":"33","author":"Zesiewicz T.","year":"2018","unstructured":"Zesiewicz T.; Heerinckx F.; De Jager R.; Omidvar O.; Kilpatrick M.; Shaw J.; Shchepinov M.S.; Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich\u2019s ataxia. Mov Disord 2018,33(6),1000-1005","journal-title":"Mov Disord"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/jacs.7b09493","volume":"140","author":"Navratil A.R.","year":"2018","unstructured":"Navratil A.R.; Shchepinov M.S.; Dennis E.A.; Lipidomics reveals dramatic physiological kinetic isotope effects during the enzymatic oxygenation of polyunsaturated fatty acids ex vivo. J Am Chem Soc 2018,140(1),235-243","journal-title":"J Am Chem Soc"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/antiox10071021","volume":"10","author":"Angelova P.R.","year":"2021","unstructured":"Angelova P.R.; Andruska K.M.; Midei M.G.; Barilani M.; Atwal P.; Tucher O.; Milner P.; Heerinckx F.; Shchepinov M.S.; RT001 in progressive supranuclear palsy-clinical and in vitro observations. Antioxidants 2021,10(7),1021","journal-title":"Antioxidants"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2010.10.690","volume":"50","author":"Hill S.","year":"2011","unstructured":"Hill S.; Hirano K.; Shmanai V.V.; Marbois B.N.; Vidovic D.; Bekish A.V.; Kay B.; Tse V.; Fine J.; Clarke C.F.; Shchepinov M.S.; Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress. Free Radic Biol Med 2011,50(1),130-138","journal-title":"Free Radic Biol Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1016\/j.xphs.2020.08.019","volume":"109","author":"Brenna J.T.","year":"2020","unstructured":"Brenna J.T.; James G.; Midei M.; Heerinckx F.; Atwal P.; Milner P.; Schmidt K.; van der Ploeg L.; Fielding R.; Shchepinov M.S.; Plasma and red blood cell membrane accretion and pharmacokinetics of RT001 (bis-Allylic 11,11-D2-Linoleic Acid Ethyl Ester) during long term dosing in patients. J Pharm Sci 2020,109(11),3496-3503","journal-title":"J Pharm Sci"},{"key":"ref=104","author":"Schepinov M.S.","year":"2012","unstructured":"Schepinov M.S.; Oxidative retinal diseases. 2012"},{"key":"ref=105","author":"Schepinov M.S.","year":"2012","unstructured":"Schepinov M.S.; Neurodegenerative disorders and muscle diseases implicating pufas. 2012"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1167\/iovs.18-26215","volume":"60","author":"Scholl H.P.","year":"2019","unstructured":"Scholl H.P.; Tsang S.H.; Kay C.N.; Stargardt disease ALK-001 phase 2 clinical trial: 12-month interim data. Invest Ophthalmol Vis Sci 2019,60(9),1336","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=107","first-page":"270","volume":"250","author":"Saad L.","year":"2015","unstructured":"Saad L.; Washington I.; Can deuterated vitamin A be used to prevent blindness? The case of ALK-001. Abstracts of Papers of the Am Chem Soc 2015,250,270","journal-title":"Abstracts of Papers of the Am Chem Soc"},{"key":"ref=108","first-page":"5015","volume":"55","author":"Issa P.C.","year":"2014","unstructured":"Issa P.C.; Barnard A.R.; Washington I.; MacLaren R.E.; C20-D3-Vitamin A (ALK-001) rescues the phenotype of an Abca4(-\/-) mouse model of Stargardt disease. Invest Ophthalmol Vis Sci 2014,55(13),5015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=109","first-page":"2685","volume":"57","author":"Scholl H.P.","year":"2016","unstructured":"Scholl H.P.; Shah S.M.; Kay C.N.; Tsang S.H.; TEASE: A phase 2 clinical trial assessing the tolerability and effects of oral once-a day ALK-001 on Stargardt disease. Invest Ophthalmol Vis Sci 2016,57(12),2685","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=110","author":"Hector F.","year":"1998","unstructured":"Hector F.; DeLuca D.; Praveen K.; Tadikonda M.; Method of synthesis of retinoic acid. 1998"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1021\/jacs.7b03480","volume":"139","author":"Adamson N.J.","year":"2017","unstructured":"Adamson N.J.; Hull E.; Malcolmson S.J.; Enantioselective intermolecular addition of aliphatic amines to acyclic dienes with a Pd\u2013PHOX Catalyst. J Am Chem Soc 2017,139(21),7180-7183","journal-title":"J Am Chem Soc"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel R.L.","year":"2019","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2019. CA Cancer J Clin 2019,69(1),7-34","journal-title":"CA Cancer J Clin"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000067996","volume":"36","author":"Palmberg C.","year":"1999","unstructured":"Palmberg C.; Koivisto P.; Visakorpi T.; Tammela T.L.J.; PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 1999,36(3),191-196","journal-title":"Eur Urol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199101243240406","volume":"324","author":"Gittes R.F.","year":"1991","unstructured":"Gittes R.F.; Carcinoma of the prostate. N Engl J Med 1991,324(4),236-245","journal-title":"N Engl J Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"321","author":"Crawford E.D.","year":"1989","unstructured":"Crawford E.D.; Eisenberger M.A.; McLeod D.G.; Spaulding J.T.; Benson R.; Dorr F.A.; Blumenstein B.A.; Davis M.A.; Goodman P.J.; A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989,321(7),419-424","journal-title":"N Engl J Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0090-4295(93)90634-M","volume":"42","author":"Denis L.J.","year":"1993","unstructured":"Denis L.J.; Carnelro D.; Moura J.L.; Bono A.; Goserelin acetate andflutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993,42(2),119-129","journal-title":"Urology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"Schalken J.","year":"2016","unstructured":"Schalken J.; Fitzpatrick J.M.; Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 2016,117(2),215-225","journal-title":"BJU Int"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"Tran C.","year":"2009","unstructured":"Tran C.; Ouk S.; Clegg N.J.; Chen Y.; Watson P.A.; Arora V.; Wongvipat J.; Smith-Jones P.M.; Yoo D.; Kwon A.; Wasielewska T.; Welsbie D.; Chen C.D.; Higano C.S.; Beer T.M.; Hung D.T.; Scher H.I.; Jung M.E.; Sawyers C.L.; Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009,324(5928),787-790","journal-title":"Science"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"Scher H.I.","year":"2012","unstructured":"Scher H.I.; Fizazi K.; Saad F.; Taplin M.E.; Sternberg C.N.; Miller K.; de Wit R.; Mulders P.; Chi K.N.; Shore N.D.; Armstrong A.J.; Flaig T.W.; Fl\u00e9chon A.; Mainwaring P.; Fleming M.; Hainsworth J.D.; Hirmand M.; Selby B.; Seely L.; de Bono J.S.; Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012,367(13),1187-1197","journal-title":"N Engl J Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.18553\/jmcp.2019.25.3-b.s1","volume":"25","author":"Wen L.","year":"2019","unstructured":"Wen L.; Yao J.; Valderrama A.; Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manage Care Spec Pharm 2019,25(3-b suppl.),S1-S11","journal-title":"J Manage Care Spec Pharm"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1124\/dmd.31.12.1481","volume":"31","author":"Nelson S.D.","year":"2003","unstructured":"Nelson S.D.; Trager W.F.; The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos 2003,31(12),1481-1497","journal-title":"Drug Metab Dispos"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/dmd.111.042770","volume":"40","author":"Sharma R.","year":"2012","unstructured":"Sharma R.; Strelevitz T.J.; Gao H.; Clark A.J.; Schildknegt K.; Obach R.S.; Ripp S.L.; Spracklin D.K.; Tremaine L.M.; Vaz A.D.N.; Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos 2012,40(3),625-634","journal-title":"Drug Metab Dispos"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11030-018-9875-7","volume":"23","author":"Zhong L.","year":"2019","unstructured":"Zhong L.; Hou C.; Zhang L.; Zhao J.; Li F.; Li W.; Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 2019,23(2),341-350","journal-title":"Mol Divers"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jlcr.3516","volume":"60","author":"Pang X.","year":"2017","unstructured":"Pang X.; Peng L.; Chen Y.; Effect of N -methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. J Labelled Comp Radiopharm 2017,60(9),401-409","journal-title":"J Labelled Comp Radiopharm"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clgc.2019.05.020","volume":"18","author":"Joulia M.L.","year":"2020","unstructured":"Joulia M.L.; Carton E.; Jouinot A.; Allard M.; Huillard O.; Khoudour N.; Peyromaure M.; Zerbib M.; Schoemann A.T.; Vidal M.; Goldwasser F.; Alexandre J.; Blanchet B.; Pharmacokinetic\/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. Clin Genitourin Cancer 2020,18(2),155-160","journal-title":"Clin Genitourin Cancer"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","volume":"68","author":"Higano C.S.","year":"2015","unstructured":"Higano C.S.; Beer T.M.; Taplin M.E.; Efstathiou E.; Hirmand M.; Forer D.; Scher H.I.; Long-term safety and anti-tumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol 2015,68(5),795-801","journal-title":"Eur Urol"},{"key":"ref=127","first-page":"27","volume":"8","author":"Golshayan A.R.","year":"2013","unstructured":"Golshayan A.R.; Antonarakis E.S.; Enzalutamide: An evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013,8,27-35","journal-title":"Core Evid"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"e17021","DOI":"10.1200\/JCO.2018.36.15_suppl.e17021","volume":"36","author":"Bi F.","year":"2018","unstructured":"Bi F.; Zheng L.; Liu J.Y.; Cheng K.; Chao P.; Zhou Y.W.; Wei Q.; Zeng H.; Shen P.F.; Shu Z.Q.; Zhou Z.X.; Zheng W.; Chen Y.W.; Li X.H.; Phase I study of HC-1119, an androgen receptor inhibitor: Results from the dose escalation and expansion cohorts. J Clin Oncol 2018,36(15),e17021","journal-title":"J Clin Oncol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ijc.33706","volume":"149","author":"Li X.","year":"2021","unstructured":"Li X.; Cheng K.; Li X.; Zhou Y.; Liu J.; Zeng H.; Chen Y.; Liu X.; Zhang Y.; Wang Y.; Bi F.; Zheng L.; Phase I clinical trial of  -1119: A deuterated form of enzalutamide. Int J Cancer 2021,149(7),1473-1482","journal-title":"Int J Cancer"},{"key":"ref=130","author":"Zhu L.J.","year":"2013","unstructured":"Zhu L.J.; Lei F.; Imidazole diketone compounds and their uses. 2013"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"631770","DOI":"10.3389\/fnagi.2021.631770","volume":"13","author":"Santiago J.A.","year":"2021","unstructured":"Santiago J.A.; Potashkin J.A.; The impact of disease comorbidities in Alzheimer\u2019s disease. Front Aging Neurosci 2021,13,631770","journal-title":"Front Aging Neurosci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","volume":"26","author":"Garay R.P.","year":"2017","unstructured":"Garay R.P.; Grossberg G.T.; AVP-786 for the treatment of agitation in dementia of the Alzheimer\u2019s type. Expert Opin Investig Drugs 2017,26(1),121-132","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/14656566.2021.1882995","volume":"22","author":"Khoury R.","year":"2021","unstructured":"Khoury R.; Marx C.; Mirgati S.; Velury D.; Chakkamparambil B.; Grossberg G.T.; AVP-786 as a promising treatment option for Alzheimer\u2019s disease including agitation. Expert Opin Pharmacother 2021,22(7),783-795","journal-title":"Expert Opin Pharmacother"},{"key":"ref=134","author":"Li X.J.Z.","year":"2014","unstructured":"Li X.J.Z.; Li J.Z.; Ma X.L.; Chi W.Z.; Liu H.; Hu X.H.; Zheng X.L.; Zhai Z.J.; Li J.X.; Method for preparing dextromethorphan. 2014"},{"key":"ref=135","author":"Yamao N.","year":"2019","unstructured":"Yamao N.; Industrial process of mono-alkylating a piperidine nitrogen in piperidine derivatives with deuterated-alkyl. 2019"},{"key":"ref=136","author":"Miyake M.","year":"2020","unstructured":"Miyake M.; Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amin. 2020"},{"key":"ref=137","first-page":"195","volume":"11","author":"Huebert N.D.","year":"1983","unstructured":"Huebert N.D.; Palfreyman M.G.; Haegele K.D.; A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine. Drug Metab Dispos 1983,11(3),195-200","journal-title":"Drug Metab Dispos"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"Olanow C.W.","year":"2009","unstructured":"Olanow C.W.; Stern M.B.; Sethi K.; The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009,72(Supplement 4),S1-S136","journal-title":"Neurology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"9832839","DOI":"10.1155\/2016\/9832839","volume":"2016","author":"Magrinelli F.","year":"2016","unstructured":"Magrinelli F.; Picelli A.; Tocco P.; Federico A.; Roncari L.; Smania N.; Zanette G.; Tamburin S.; Pathophysiology of motor dysfunction in Parkinson\u2019s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016,2016,9832839","journal-title":"Parkinsons Dis"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neures.2022.02.001","volume":"178","author":"Nishijima H.","year":"2022","unstructured":"Nishijima H.; Mori F.; Kimura T.; Miki Y.; Kinoshita I.; Nakamura T.; Kon T.; Suzuki C.; Wakabayashi K.; Tomiyama M.; Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson\u2019s disease. Neurosci Res 2022,178,93-97","journal-title":"Neurosci Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"19496","DOI":"10.1074\/jbc.M501854200","volume":"280","author":"Krauser J.A.","year":"2005","unstructured":"Krauser J.A.; Guengerich F.P.; Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005,280(20),19496-19506","journal-title":"J Biol Chem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00702-014-1247-6","volume":"122","author":"Malml\u00f6f T.","year":"2015","unstructured":"Malml\u00f6f T.; Feltmann K.; Konradsson-Geuken \u00c5.; Schneider F.; Alken R.G.; Svensson T.H.; Schilstr\u00f6m B.; Deuterium-substituted l-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson\u2019s disease: Comparison with the effects produced by l-DOPA and an MAO-B inhibitor. J Neural Transm (Vienna) 2015,122(2),259-272","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.expneurol.2008.05.003","volume":"212","author":"Malml\u00f6f T.","year":"2008","unstructured":"Malml\u00f6f T.; Svensson T.H.; Schilstr\u00f6m B.; Altered behavioural and neurochemical profile of l-DOPA following deuterium substitutions in the molecule. Exp Neurol 2008,212(2),538-542","journal-title":"Exp Neurol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.expneurol.2010.07.018","volume":"225","author":"Malml\u00f6f T.","year":"2010","unstructured":"Malml\u00f6f T.; Rylander D.; Alken R.G.; Schneider F.; Svensson T.H.; Cenci M.A.; Schilstr\u00f6m B.; Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Exp Neurol 2010,225(2),408-415","journal-title":"Exp Neurol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2125.2002.01654.x","volume":"54","author":"Heikkinen H.","year":"2002","unstructured":"Heikkinen H.; Varhe A.; Laine T.; Puttonen J.; Kela M.; Kaakkola S.; Reinikainen K.; Entacapone improves the availability of L-DOPA in plasma by decreasing its peripheral metabolism independent of L-DOPA\/carbidopa dose. Br J Clin Pharmacol 2002,54(4),363-371","journal-title":"Br J Clin Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1111\/bcp.13702","volume":"84","author":"Schneider F.","year":"2018","unstructured":"Schneider F.; Erisson L.; Beygi H.; Bradbury M.; Cohen-Barak O.; Grachev I.D.; Guzy S.; Loupe P.S.; Levi M.; McDonald M.; Savola J.M.; Papapetropoulos S.; Tracewell W.G.; Velinova M.; Spiegelstein O.; Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)\/carbidopa compared to L-DOPA\/carbidopa following single oral dose administration in healthy subjects. Br J Clin Pharmacol 2018,84(10),2422-2432","journal-title":"Br J Clin Pharmacol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1016\/S0924-977X(16)31127-0","volume":"26","author":"Alken R.","year":"2016","unstructured":"Alken R.; Malml\u00f6f T.; Feltmann K.; Konradsson-Geuken A.; Schneider F.; Schilstr\u00f6m B.; Svensson T.H.; Less dyskinesia at motor-equivalent doses of triple-deuterated L-DOPA vs. L-DOPA after chronic administration in rats. Eur Neuropsychopharmacol 2016,26,S253-S254","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=148","author":"Russ H.","year":"2017","unstructured":"Russ H.; Mandel S.A.; Moshav A.H.; Arie S.; Orbach A.; Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson's disease. 2017"},{"key":"ref=149","author":"Harbeson S. L.","year":"2015","unstructured":"Harbeson S. L.; Deuterium medicinal chemistry: From bench to clinic. NERM-345, New Haven, CT, USA 2015","journal-title":"NERM-345, New Haven, CT, USA"},{"key":"ref=150","first-page":"310","volume":"250","author":"Harbeson S.L.","year":"2015","unstructured":"Harbeson S.L.; Deuterium-modified drugs: Discovery and development. Am Chem Soc 2015,250,310","journal-title":"Am Chem Soc"},{"key":"ref=151","author":"Harbeson S.","year":"2010","unstructured":"Harbeson S.; Substituted triazolo-pyridazine derivatives for the treatment of diseases associated with certain GABA-A receptors. 2010"},{"key":"ref=152","author":"Igo D.","year":"2013","unstructured":"Igo D.; Bis J.; Weissman S.; Turnquist D.; Preparation of polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine. 2013"},{"key":"ref=153","first-page":"277","volume":"51","author":"Uttamsingh V.","year":"2016","unstructured":"Uttamsingh V.; Pilja L.; Brummel C.L.; Grotbeck B.; Cassella J.V.; Braman G.; CTP-656 multiple dose pharmacokinetic profile continues to support a once-daily potentiator for cystic fibrosis patients with gating mutations. Pediatr Pulmonol 2016,51,277-277","journal-title":"Pediatr Pulmonol"},{"key":"ref=154","author":"Altshuler D.M.","year":"2020","unstructured":"Altshuler D.M.; Anderson C.D.; Chen W.C.; Clemens J.J.; Cleveland T.; Coon T.R.; Frieman B.; Grootenhuis P.; Hadida R.S.S.; Hare B.J.; Kewalramani R.; McCartney J.; Miller M.T.; Paraselli P.; Pierre F.; Robertson S.M.; Sosnay P.R.; Swift S.E.; Zhou J.L.; Preparation of macrocyclic compound for treating cystic fibrosis. 2020"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2014.05.043","volume":"963","author":"Tang X.","year":"2014","unstructured":"Tang X.; Bridson G.; Ke J.; Wu L.; Erol H.; Graham P.; Lin C.H.; Braman V.; Zhao H.; Liu J.F.; Lin Z.J.; Cheng C.; Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2014,963(963),1-9","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","volume":"52","author":"McCormick B.B.","year":"2008","unstructured":"McCormick B.B.; Sydor A.; Akbari A.; Fergusson D.; Doucette S.; Knoll G.; The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. Am J Kidney Dis 2008,52(3),454-463","journal-title":"Am J Kidney Dis"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"Levey A.S.","year":"2009","unstructured":"Levey A.S.; Cattran D.; Friedman A.; Miller W.G.; Sedor J.; Tuttle K.; Kasiske B.; Hostetter T.; Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009,54(2),205-226","journal-title":"Am J Kidney Dis"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"Brenner B.M.","year":"2001","unstructured":"Brenner B.M.; Cooper M.E.; de Zeeuw D.; Keane W.F.; Mitch W.E.; Parving H.H.; Remuzzi G.; Snapinn S.M.; Zhang Z.; Shahinfar S.; Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001,345(12),861-869","journal-title":"N Engl J Med"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1681\/ASN.2007091048","volume":"19","author":"Navarro-Gonz\u00e1lez J.F.","year":"2008","unstructured":"Navarro-Gonz\u00e1lez J.F.; Mora-Fern\u00e1ndez C.; The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008,19(3),433-442","journal-title":"J Am Soc Nephrol"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cpdd.241","volume":"5","author":"Sabounjian L.","year":"2016","unstructured":"Sabounjian L.; Graham P.; Wu L.J.; Braman V.; Cheng C.F.; Liu J.L.; Shipley J.; Neutel J.; Dao M. A; A first-in-patient, multicenter, double-blind, 2-ARM, placebo-controlled, randomized safety and tolerability study of a novel oral drug candidate, CTP-499, in chronic kidney disease. Clin Pharm Drug Dev 2016,5(4),314-325","journal-title":"Clin Pharm Drug Dev"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"iii32","DOI":"10.1093\/ndt\/gfs113","volume":"27","author":"Jha V.","year":"2012","unstructured":"Jha V.; Wang A.Y.M.; Wang H.; The impact of CKD identification in large countries: The burden of illness. Nephrol Dial Transplant 2012,27(Suppl. 3),iii32-iii38","journal-title":"Nephrol Dial Transplant"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"B38","DOI":"10.1053\/j.ajkd.2012.02.102","volume":"59","author":"Graham P.","year":"2012","unstructured":"Graham P.; Sabounjian L.; Shipley J.; Braman V.; Harnett M.; Turnquist D.; Cheng C.F.; Wu L.J.; Safety, tolerability and pharmacokinetics of CTP-499 in a multi-center, double-blind, two-arm, placebo-controlled, randomized study in non-dialysis patients with stage 3 chronic kidney disease. Am J Kidney Dis 2012,59(4),B38","journal-title":"Am J Kidney Dis"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"B120","DOI":"10.1053\/j.ajkd.2014.01.446","volume":"63","author":"Singh B.","year":"2014","unstructured":"Singh B.; Diamond S.A.; Pergola P.E.; Shipley J.E.; Wu L.J.; Sabounjian L.A.; Graham P.B.; Effect of CTP-499 on renal function in patients with type 2 diabetes and kidney disease. Am J Kidney Dis 2014,63(5),B120","journal-title":"Am J Kidney Dis"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cpdd.3","volume":"2","author":"Braman V.","year":"2013","unstructured":"Braman V.; Graham P.; Cheng C.; Turnquist D.; Harnett M.; Sabounjian L.; Shipley J.; A randomized phase I evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy. Clin Pharmacol Drug Dev 2013,2(1),53-66","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/cr50004a004","volume":"55","author":"Wiberg K.B.","year":"1955","unstructured":"Wiberg K.B.; The deuterium isotope effect. Chem Rev 1955,55(4),713-743","journal-title":"Chem Rev"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1021\/acs.jpca.1c08514","volume":"126","author":"Kimura Y.","year":"2022","unstructured":"Kimura Y.; Kanematsu Y.; Sakagami H.; Rivera Rocabado D.S.; Shimazaki T.; Tachikawa M.; Ishimoto T.; Hydrogen\/deuterium transfer from anisole to methoxy radicals: A theoretical study of a deuterium-labeled drug model. J Phys Chem A 2022,126(1),155-163","journal-title":"J Phys Chem A"},{"key":"ref=167","author":"Parasrampuria D.","year":"2011","unstructured":"Parasrampuria D.; Braman V.; Cheng C.; Grotbeck B.; First human exposure suggests a unique metabolic profile with multiple active species for CTP-499, a novel agent for treatment of chronic kidney disease. ASN Poster, THPO358 2011","journal-title":"ASN Poster, THPO358"},{"key":"ref=168","first-page":"8","volume":"2","author":"Harbeson S.","year":"2014","unstructured":"Harbeson S.; Tung R.; Deuterium medicinal chemistry: A new approach to drug discovery and development. Med Chem News 2014,2,8-22","journal-title":"Med Chem News"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1440-1797.2004.00267.x","volume":"9","author":"Lin S.L.","year":"2004","unstructured":"Lin S.L.; Chen Y.M.; Chiang W.C.; Tsai T.J.; Chen W.Y.; Review Article. Pentoxifylline: A potential therapy for chronic kidney disease. Nephrology (Carlton) 2004,9(4),198-204","journal-title":"Nephrology (Carlton)"},{"key":"ref=170","author":"Aslanian A.","year":"2012","unstructured":"Aslanian A.; Hogan K.; West K.; Bridson G.; Wu L.; CTP-499, a novel drug for the treatment of chronic kidney disease, ameliorates renal fibrosis and inflammation in vivo. ASN. ASN Poster 2012","journal-title":"ASN Poster"},{"key":"ref=171","author":"Aslanian A.","year":"2011","unstructured":"Aslanian A.; Hogan K.; Qin S.; CTP-499, a novel drug for the potential treatment of chronic kidney disease, has anti-fibrotic, anti-inflammatory, and anti-oxidative activities with in vivo efficacy. ASN Poster 2011","journal-title":"ASN Poster"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"128","DOI":"10.18433\/J3BP4G","volume":"14","author":"Badri S.","year":"2011","unstructured":"Badri S.; Dashti-Khavidaki S.; Lessan-Pezeshki M.; Abdollahi M.; A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharm Sci 2011,14(1),128-137","journal-title":"J Pharm Pharm Sci"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2005080859","volume":"17","author":"Galkina E.","year":"2006","unstructured":"Galkina E.; Ley K.; Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006,17(2),368-377","journal-title":"J Am Soc Nephrol"},{"key":"ref=174","first-page":"790","volume":"32","author":"Ghorbani A.","year":"2012","unstructured":"Ghorbani A.; Omidvar B.; Beladi-Mousavi S.S.; Lak E.; Vaziri S.; The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 2012,32(6),790-796","journal-title":"Nefrologia"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5414\/CNP66003","volume":"66","author":"Rodr\u00edguez-Mor\u00e1n M.","year":"2006","unstructured":"Rodr\u00edguez-Mor\u00e1n M.; Gonz\u00e1lez-Gonz\u00e1lez G.; Berm\u00fadez-Barba M.V.; Garza C.E.M.; Tamez-P\u00e9rez H.E.; Mart\u00ednez-Mart\u00ednez F.J.; Guerrero-Romero F.; Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria \u2013 A double-blind, placebo-controlled randomized trial. Clin Nephrol 2006,66(7),3-10","journal-title":"Clin Nephrol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cpdd.3","volume":"2","author":"Braman V.","year":"2013","unstructured":"Braman V.; Graham P.; Cheng C.; Turnquist D.; Harnett M.; Sabounjian L.; Shipley J.; A randomized phase 1 evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy. Clin Pharmacol Drug Dev 2013,2(1),53-66","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=177","author":"Tung R.D.","year":"2011","unstructured":"Tung R.D.; Liu J.F.; Harbeson S.L.; Preparation of deuterated xanthine derivatives for pharmaceutical use. 2011"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/j.jid.2018.03.1073","volume":"138","author":"Hogan K.","year":"2018","unstructured":"Hogan K.; Uttamsingh V.; Hamilton C.; Aslanian A.; Brummel C.; Braman V.; Cassella J.; Wong D.; 1060 JAK inhibitor CTP-543: Modeled exposure-response profile suggests improved therapeutic window. J Invest Dermatol 2018,138(5),S180-S180","journal-title":"J Invest Dermatol"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"AB225","DOI":"10.1016\/j.jaad.2017.04.877","volume":"76","author":"Von Hehn J.","year":"2017","unstructured":"Von Hehn J.; Hamilton C.; Uttamsingh V.; Hogan K.; Aslanian A.M.; Grotbeck B.; Brummel C.L.; Braman V.; Cassella J.; Safety, pharmacokinetic and pharmacodynamic evaluation of CTP-543 (deuterated ruxolitinib) in a phase I healthy volunteer study. J Am Acad Dermatol 2017,76(6),AB225-AB225","journal-title":"J Am Acad Dermatol"},{"key":"ref=180","author":"Silverman I.R.","year":"2015","unstructured":"Silverman I.R.; Liu J.F.; Morgan A.J.; Pandya B.; Harbeson S.L.; Deuterium-substituted derivative of ruxolitinib. 2015"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5582\/bst.2020.03106","volume":"14","author":"Meng X.","year":"2020","unstructured":"Meng X.; Ling Y.; Zhang L.; Zhang Q.; Dong P.; Zhu T.; Lu H.; Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. Biosci Trends 2020,14(3),161-167","journal-title":"Biosci Trends"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"604314","DOI":"10.3389\/fphar.2020.604314","volume":"11","author":"Liu J.","year":"2020","unstructured":"Liu J.; Lv B.; Yin H.; Zhu X.; Wei H.; Ding Y.; A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the tolerance, pharmacokinetics of jaktinib, a new selective janus kinase inhibitor in healthy chinese volunteers. Front Pharmacol 2020,11,604314","journal-title":"Front Pharmacol"},{"key":"ref=183","author":"Lv B.H.","year":"2014","unstructured":"Lv B.H.; Sheng Z.L.; Cao B.W.; Deuterated (phenylamino)pyrimidine compounds as JAK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. 2014"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"vi122","DOI":"10.1093\/annonc\/mdw368.25","volume":"27","author":"Boucher D.","year":"2016","unstructured":"Boucher D.; Hillier S.; Newsome D.; Wang Y.; Takemoto D.; Gu Y.; Markland W.; Hoover R.; Arimoto R.; Maxwell J.; Fields S.Z.; Charifson P.; Penney M.S.; Tanner K.; Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy. Ann Oncol 2016,27,vi122","journal-title":"Ann Oncol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"P5-06-05","DOI":"10.1158\/1538-7445.SABCS16-P5-06-05","volume":"77","author":"Boucher D.","year":"2017","unstructured":"Boucher D.; Newsome D.; Takemoto D.; Hillier S.; Wang Y.; Arimoto R.; Maxwell J.; Charifson P.; Fields S.Z.; Tanner K.; Penney M.S.; Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers. Cancer Res 2017,77(4),P5-06-05","journal-title":"Cancer Res"},{"key":"ref=186","volume":"251","author":"Maxwell J.","year":"2016","unstructured":"Maxwell J.; Cottrell K.; Xu J.W.; Arimoto R.; Discovery of VX-984: A novel, selective DNA-PK inhibitor for the treatment of cancer. Am Chem Soc 2016,251","journal-title":"Am Chem Soc"},{"key":"ref=187","first-page":"251","author":"Cottrell K.","year":"2016","unstructured":"Cottrell K.; Boucher B.; Arimoto R.; Engtrakul J.; Discovery of VX-984: Mitigation of aldehyde oxidase metabolism through the use of targeted deuteration. Am Chem Soc 2016,251","journal-title":"Am Chem Soc"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","volume":"17","author":"Timme C.R.","year":"2018","unstructured":"Timme C.R.; Rath B.H.; O\u2019Neill J.W.; Camphausen K.; Tofilon P.J.; The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts. Mol Cancer Ther 2018,17(6),1207-1216","journal-title":"Mol Cancer Ther"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1158\/1538-7445.AM2016-3716","volume":"76","author":"Boucher D.","year":"2016","unstructured":"Boucher D.; Hoover R.; Wang Y.; Gu Y.; Newsome D.; Ford P.; Moody C.; Damagnez V.; Arimoto R.; Hillier S.; Wood M.; Markland W.; Eustace B.; Cottrell K.; Penney M.; Furey B.; Tanner K.; Maxwell J.; Charifson P.; Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. Cancer Res 2016,76(14 Suppl.),3716","journal-title":"Cancer Res"},{"key":"ref=190","author":"Charifson P.S.","year":"2014","unstructured":"Charifson P.S.; Cottrell K.M.; Deng H.B.; Duffy J.P.; Gao H.; Giroux S.; Green J.; Jackson K.L.; Kennedy J.M.; Lauffer D.J.; Ledeboer M.W.; Li P.; Maxwell J.P.; Morris M.A.; Pierce A.C.; Waal N.D.; Xu J.W.; DNA-PK inhibitors. 2014"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1021\/jo00391a029","volume":"52","author":"Reider P.J.","year":"1987","unstructured":"Reider P.J.; Conn R.S.E.; Davis P.; Grenda V.J.; Zambito A.J.; Grabowski E.J.J.; Synthesis of (R)-serine-2-d and its conversion to the broad-spectrum antibiotic fludalanine. J Org Chem 1987,52(15),3326-3334","journal-title":"J Org Chem"},{"key":"ref=192","author":"Doller D.","year":"2020","unstructured":"Doller D.; Brummel C.L.; Liu J.F.; Tung R.D.; Wong D.H.; Petryshen T.L.; Hurst R.S.; Deuterated analogs of D-serine and uses thereof. 2020"},{"key":"ref=193","author":"Wu Y.S.","year":"2017","unstructured":"Wu Y.S.; Niu C.S.; Geng Y.; Zheng M.L.; Liang A.; Meng Q.G.; Yang T.; Wang G.H.; Huo Y.F.; Guo R.Y.; Li J.Y.; Zou D.P.; Preparation of deuterated palbociclib derivatives as antitumor agents. 2017"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221122123201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211124\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221122123201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:54:52Z","timestamp":1693670092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211124\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":193,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666221122123201","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}